C1-esterase inhibitor treatment for antibody-mediated rejection after lung transplantation: two case reports
- 20 February 2020
- journal article
- letter
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 55 (4), 1902027
- https://doi.org/10.1183/13993003.02027-2019
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Current challenges and opportunities in the management of antibody-mediated rejection in lung transplantationCurrent Opinion in Organ Transplantation, 2018
- Plasma-Derived C1 Esterase Inhibitor for Acute Antibody-Mediated Rejection Following Kidney Transplantation: Results of a Randomized Double-Blind Placebo-Controlled Pilot StudyAmerican Journal of Transplantation, 2016
- Eculizumab Therapy for Chronic Antibody-Mediated Injury in Kidney Transplant Recipients: A Pilot Randomized Controlled TrialAmerican Journal of Transplantation, 2016
- C1 Inhibitor in Acute Antibody-Mediated Rejection Nonresponsive to Conventional Therapy in Kidney Transplant Recipients: A Pilot StudyAmerican Journal of Transplantation, 2016
- Antibody-mediated rejection of the lung: A consensus report of the International Society for Heart and Lung TransplantationThe Journal of Heart and Lung Transplantation, 2016
- Antibody-Mediated Rejection in Lung Transplantation: Clinical Outcomes and Donor-Specific Antibody CharacteristicsAmerican Journal of Transplantation, 2016
- Positive Crossmatch Kidney Transplant Recipients Treated With Eculizumab: Outcomes Beyond 1 YearAmerican Journal of Transplantation, 2015
- A Phase I/II Placebo-Controlled Trial of C1-Inhibitor for Prevention of Antibody-Mediated Rejection in HLA Sensitized PatientsTransplantation, 2015
- Antibody-mediated rejection despite inhibition of terminal complementTransplant International, 2014
- Terminal Complement Inhibition Decreases Antibody-Mediated Rejection in Sensitized Renal Transplant RecipientsAmerican Journal of Transplantation, 2011